Document Detail


Thrombin/antithrombin III complex formation in the neonatal respiratory distress syndrome.
MedLine Citation:
PMID:  1554199     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Intravascular and intra-alveolar thrombin generation may exacerbate the pulmonary hypertension and surfactant dysfunction that characterize the neonatal respiratory distress syndrome (RDS). Although low levels of the most important thrombin inhibitor, antithrombin III (AT III), have been reported in infants with RDS, direct evidence of increased intravascular thrombin generation has been lacking. Accordingly, the objective of this study was to determine whether thrombin generation is increased in severe neonatal RDS. Thirty-nine infants of 25 to 29 wk gestation with a clinical and radiologic diagnosis of RDS were enrolled in a prospective cohort study. Plasma levels of thrombin/antithrombin III complexes (TAT) and AT III activity, measured 36 to 72 h after birth, were related to RDS severity. Seventeen infants had severe RDS (mean airway pressure greater than 10 cm H2O or FlO2 greater than 0.8), and 22 had mild or moderate disease. Mean birthweight (1,017 versus 1,054 g) and mean gestational age (27.8 versus 27.4 wk) were similar in both groups. The median TAT level in infants with severe RDS was significantly higher than that in patients with mild or moderate disease (10.7 and 4.0 micrograms/L, respectively; p less than 0.001). In addition, the mean AT III activity in infants with severe RDS was significantly lower than that in less severely affected patients (0.31 and 0.46 U/ml, respectively; p less than 0.01). Considering the entire cohort, plasma TAT levels were inversely correlated with the arterial/alveolar oxygen tension ratio (r = -0.48, p = 0.0022) and the ventilator efficiency index (r = -0.51, p = 0.0011). The elevated TAT levels and reduced AT III activity in infants with severe RDS are consistent with increased thrombin generation and resulting AT III consumption. Therefore, to regulate thrombin activity, these infants may benefit from replacement therapy with AT III concentrate.
Authors:
B Schmidt; P Vegh; J Weitz; M Johnston; C Caco; R Roberts
Related Documents :
12193669 - Steroids fail to down-regulate respiratory syncytial virus-induced il-8 secretion in in...
8662029 - Respiratory syncytial virus infection in children with congenital heart disease: a review.
12615029 - Current strategies in the prevention of respiratory syncytial virus disease.
19490659 - Cost-utility analysis of palivizumab in italy: results from a simulation model in the p...
23414429 - The impact of preterm birth and bronchopulmonary dysplasia on the developing lung: long...
327959 - Clinical spectrum of infantile lobar emphysema.
1719929 - Dietary manipulation for treating infants with prolonged dehydrating diarrhoea: a compa...
9805309 - Dilation of the ventriculus terminalis: sonographic findings.
9099759 - Meta-analyses of the effectiveness of intravenous immune globulin for prevention and tr...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American review of respiratory disease     Volume:  145     ISSN:  0003-0805     ISO Abbreviation:  Am. Rev. Respir. Dis.     Publication Date:  1992 Apr 
Date Detail:
Created Date:  1992-04-30     Completed Date:  1992-04-30     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0370523     Medline TA:  Am Rev Respir Dis     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  767-70     Citation Subset:  AIM; IM    
Affiliation:
Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antithrombin III / metabolism*
Birth Weight
Blood Coagulation Tests
Cohort Studies
Female
Humans
Infant, Newborn
Male
Peptide Hydrolases / metabolism*
Prospective Studies
Respiratory Distress Syndrome, Newborn / blood*,  epidemiology
Chemical
Reg. No./Substance:
0/antithrombin III-protease complex; 9000-94-6/Antithrombin III; EC 3.4.-/Peptide Hydrolases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of elastin peptide concentrations in body fluids from healthy volunteers, smokers, and pa...
Next Document:  Increased right ventricular compliance in response to continuous positive airway pressure.